购物车
- 全部删除
- 您的购物车当前为空
Thalidomide-O-C7-acid is a compound created through the synthesis of an E3 ligase ligand-linker conjugate. It consists of a cereblon ligand derived from Thalidomide, combined with a linker that is commonly employed in PROTAC technology.
Thalidomide-O-C7-acid is a compound created through the synthesis of an E3 ligase ligand-linker conjugate. It consists of a cereblon ligand derived from Thalidomide, combined with a linker that is commonly employed in PROTAC technology.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 3,530 | 35日内发货 |
产品描述 | Thalidomide-O-C7-acid is a compound created through the synthesis of an E3 ligase ligand-linker conjugate. It consists of a cereblon ligand derived from Thalidomide, combined with a linker that is commonly employed in PROTAC technology. |
体外活性 | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2]. |
别名 | Thalidomide-O-C7-acid |
分子量 | 416.43 |
分子式 | C21H24N2O7 |
CAS No. | 2169266-70-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容